Psychedelic Toad Venom Clinical Research Boosted by $80M in Funding
Oxford-based startup Beckley Psytech in the United Kingdom announced August 15 that it raised $80 million to ramp up clinical trials and research using a pharmaceutical formulation of 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), a powerful compound produced endogenously by Sonoran Desert toad venom, to treat depression. The Series B financing was initially set at $50 million—but was upgraded… Keep Reading
